No Data
AViC, MicroAd, and others
GMonster established a subsidiary. Wilsmart entered into a capital and business alliance with Izumiyō Kōgyō, which handles the comprehensive planning, development, construction, and management of amusement parks, various entertainment venues, and parks, through a third-party allotment of new shares (699,600 shares). The research and license agreement between PRISM Bio and Boehringer Ingelheim International GmbH has ended due to the expiration of the contract period. HMCOM is undertaking the next-generation AI implementation project.
DWTI's Bondlido Gains U.S. Sales Partner as Launch Plans Advance
One company disclosed, and twelve companies postponed their Q1 and Q3 earnings announcements as of April 14th, under the going concern assumption.
Among the earnings briefings for the first and third quarters disclosed on May 14, one listed company included a note regarding the going concern assumption due to the presence of events or conditions that raise significant doubt about the company’s ability to continue as a going concern. The company in question is as follows: ▽ Fiscal Year Ending June 2026, Third Quarter <3808> OKWeb. Additionally, although there were events or conditions that raised significant doubt, certain companies opted not to include such a note, citing reasons such as the elimination or mitigation measures that removed significant uncertainty regarding the going concern assumption.
D.Western Therapeutics Posts Deeper Quarterly Loss and Cuts 2026 Sales Outlook
D. Western Therapeutics Institute: First Quarter Earnings Release for the Fiscal Year Ending December 2026 (Japanese GAAP, Consolidated)
Shareholding change report: DWTI (11.07% → 9.00%) by Yukiichi Hidaka.
Submitter: Yūichi Hidaka Submission Date and Time: May 13, 2026, 11:06 Submitted Document: Amendment Report (Cover Page = Amendment Report No. 12) Reporting Obligation Trigger Date: May 12, 2026 Reason for Amendment Submission: The holding percentage of stock certificates, etc., decreased by more than 1%. Issuer: <4576> De Western Therapeutics Research Institute Co., Ltd. [Submitter/1]: Yūichi Hidaka